Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
An Open-Label, Phase 1/Phase 2 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of the DNA Minor Groove Binding Agent SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
  • Phase

    Phase 1/Phase 2
  • Study Type

  • Status

  • Intervention/Treatment

    sg2000 ...
  • Study Participants

The purpose of this study is to determine if the experimental drug, SG2000 is safe and tolerable in the treatment of participants with advanced chronic lymphocytic leukemia and acute myeloid leukemia whose standard treatment did not work, whose cancer came back or who are not candidates for other types of standard therapy.
Study Started
Apr 30
Primary Completion
Jun 30
Study Completion
Jun 30
Last Update
Nov 23

Drug SG2000

intravenous doses given on Days 1, 2, and 3 of each 21-day cycle (1 to 6 cycles).

  • Other names: DNA minor groove binding agent

SG2000 - 15 µg/m2/day Experimental

Cohort 1 - will commence at 15 µg/m2/day intravenous doses of SG2000 until Maximum Tolerated Dose is determined.

SG2000 - 30 µg/m2/day Experimental

Cohort 2 - will commence at 30 µg/m2/day intravenous doses of SG2000 until Maximum Tolerated Dose is determined.


Inclusion Criteria:

male or female greater than or equal to 18 years of age
have one of the following disease states: Acute Myeloid Leukemia (AML) (age <60 years) with relapsed/refractory disease; •Chronic Lymphocytic Leukemia (CLL) with relapsed disease following a fludarabine-based regimen or relapsed disease following an alkylator-based regimen
are recovered from the acute adverse effects of prior therapies (excluding alopecia and Grade ≤2 neuropathy).
have blast counts that can be controlled by the use of hydroxycarbamide (500 to 3000 mg daily).
have adequate hepatic function and renal function
have an estimated life expectancy of >3 months
female subject must have a negative serum pregnancy result within 7 days before the start of the study; Both men and women must agree to use a medically acceptable form of contraception throughout the treatment period and for 3 months after discontinuation of treatment

Exclusion Criteria:

are eligible for any standard therapy known to be life prolonging or life saving
have diagnosis of AML French-American-British (FAB) classification (FAB) M3 (acute promyelocytic leukemia (APL))
are receiving concurrent chemotherapy, radiotherapy, immunotherapy, biological or hormonal treatment for cancer.
have undergone anticancer therapy including chemotherapy (except for hydroxycarbamide at a maximum daily dose of 3000 mg), endocrine therapy, immunotherapy, or the use of other investigational agents within 4 weeks before study entry.
prior radiation therapy with volume of bone marrow treated over 25%.
use of immunosuppressive therapy, including systemic steroids within 7 days before the first dose of SG2000.
hyperleukocytosis (blast counts >30 000/mm3).
history of allogeneic stem cell or solid organ transplantation.
positive serology for human immunodeficiency virus (HIV), hepatitis B or hepatitis C or have HIV-AIDS, or active hepatitis B or C.
history of other invasive malignancy within 3 years except for cervical carcinoma in situ, nonmelanomatous carcinoma of the skin or ductal carcinoma in situ of the breast that has been surgically cured.
have any coexisting medical condition that will substantially increase the risk associated with the subject's participation in the study.
have psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of necessary studies.
have persistent Grade 2 or greater toxicities from any cause (except alopecia or peripheral neuropathy).
are pregnant or breast-feeding.
No Results Posted